Novogen (NRT:ASX) announced details of preclinical studies which is said confirm the efficacy of anti-tropomyosin (ATM) compound, Anisina, when delivered using a clinically relevant formulation, mode of administration and dosing regimen.
Presenting at the ‘American Association for Cancer Research Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship’ conference in in the US, Justine Stehn PhD, Novogen Anti-Tropomyosin Program Director, said: “These data validate the strategic decision to develop the Anisina drug candidate. We have shown that intravenously administered Anisina dosed less frequently in a preclinical study retained anti-cancer activity as a monotherapy, and enhanced the efficacy of a drug commonly used to treat pediatric neuroblastoma”.
“Based on these data we have now identified the Anisina drug candidate to be progressed into preclinical safety studies, and, pending successful completion of those safety studies, into our clinical development programs in adult and pediatric indications,” added Dr Stehn.
According to Lead Investigator Dr Timothy Cripe MD, PhD, from Nationwide Children’s Hospital, in Columbus Ohio, “This is a key proof-of-concept study and confirmed the clinical potential for this class of drug in the treatment of neuroblastoma.
“This class of compounds now has the potential to improve the effectiveness of standard-of-care chemotherapeutics such as vincristine (VCR),” Dr Cripe added.